Samuel Broder

Samuel E.
Broder is currently serving as the Director at Catalytic IP, Inc., Geneos Therapeutics, Inc., Orion Biotech Opportunities Corp., National Academy of Sciences, and National Academy of Medicine (United States).
Previously, he held positions as the Director at Protein Design Labs, Inc., AbVitro LLC, and Panacea Pharmaceuticals, Inc. He also served as the Director at the National Cancer Institute from 1972 to 1995.
Additionally, he was the Director at PDL BioPharma, Inc. from 2005 to 2007, and a Non-Executive Director at ADC Therapeutics SA. Furthermore, he held the position of Director at Sapience Therapeutics, Inc. and served as the Chief Scientific Officer and SVP-Research & Dev at IVAX LLC from 1995 to 1998.
He was also the Senior Vice President & Head-Health Sector at Precigen, Inc. from 2014 to 2016, and the Chief Medical Officer & Vice President at Celera Corp.
from 1998 to 2010.
Dr. Broder obtained his undergraduate degree from the University of Michigan and his doctorate from the University of Michigan Medical School in 1970.